Clinical Trial Detail

NCT ID NCT03347617
Title Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

glioblastoma multiforme

melanoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.